The suitability of treating atopic dermatitis with Janus kinase inhibitors

References

• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Garg N, Silverberg NB. New developments in comorbidities of atopic dermatitis. Cutis. 2014 May;93(5):222–224.
   PubMed Web of Science ®Google Scholar
• FDA US. HIGHLIGHTS OF PRESCRIBING INFORMATION; CIBINQOTM (abrocitinib) tablets, for oral use. FDA US. editor. Pfizer; 2022. https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf
   Google Scholar
• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006 Aug 26;368(9537):733–743.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis: Contact, Atopic, Occupational, Drug. 2014 May-Jun;25(3):107–114.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, et al. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol. 2018;121(6):729–734.e4.
   PubMed Web of Science ®Google Scholar
• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018 Jun;73(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Dennis M, Bhutani T, Koo J, et al. Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. J Dermatolog Treat. 2013;24(1):2–6.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2.
   PubMed Web of Science ®Google Scholar
• Ud Din A T, Malik I, Arshad D, et al. Dupilumab for atopic dermatitis: the silver bullet we have been searching for?. Cureus. 2020;12(4):e7565.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449.
   Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463.
   Web of Science ®Google Scholar
• Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol. 2013 Sep;132(3):774–774.e6.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. The Journal of Allergy and Clinical Immunology in Practice. 2017 Nov-Dec;5(6):1519–1531.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol JEADV. 2018 Jun;32:850–878.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Kircik L, Zirwas M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: phase 2 proof-of-concept study. SKIN J Cutaneous Med. 2020 Oct 27;4(6):s93.
   Google Scholar
• Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021 Mar;84(3):632–638.
   PubMed Web of Science ®Google Scholar
• Eichenfeld L, Silverberg J, Bissonnette R, et al. Tapinarof cream 1% once daily for the treatment of moderate to severe atopic dermatitis in children and adults: the pivotal phase 3 ADORING clinical program. SKIN J Cutaneous Med. 2021 Nov 5;5(6):s62.
   Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020 Jul 9;383(2):141–150.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411–420.
   PubMed Web of Science ®Google Scholar
• Loh TY, Hsiao JL, Shi VY. therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020;13:109–114.
   PubMed Web of Science ®Google Scholar
• Bieber T, Simpson EL, Silverberg JI, et al., Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 384(12): 1101–1112. 2021.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017 Apr;139(4):S65–s76.
   PubMed Web of Science ®Google Scholar
• Egawa G, Weninger W. Pathogenesis of atopic dermatitis: a short review. Cogent Biology. 2015; Dec 31;1(1):1103459.
   Web of Science ®Google Scholar
• Bureau USC Quick facts United States 2019. [cited 2022 Jan 15]. Available from: https://www.census.gov/quickfacts/fact/table/US/HSG010218#HSG010218
   Google Scholar
• Virtanen A T, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019 Feb 1;33(1):15–32.
   PubMed Web of Science ®Google Scholar
• Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020;31(Suppl 1):100–104
   PubMedGoogle Scholar
• Howell MD, Kuo FI, Smith PA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487.
   PubMed Web of Science ®Google Scholar
• Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway [10.1002/pro.3519]. Protein Sci. 2018 Dec 1;27(12):1984–2009.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Cumano A, Müller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitivehematopoiesis. Cell. 1998 May 1;93(3):397–409.
   PubMed Web of Science ®Google Scholar
• Notarangelo LD, Giliani S, Mazza C, et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev. 2000 Dec;178(1):39–48.
   PubMedGoogle Scholar
• Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–875.
   PubMed Web of Science ®Google Scholar
• Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase iia trials. Arthritis Rheumatol (Hoboken). 2017;69(10):1949–1959.
   PubMed Web of Science ®Google Scholar
• Targum SL, editor. Opzelura (ruxolitinib cream). Silver Spring, MD: Administration FUSFD. 2021.
   Google Scholar
• FDA Approves Ruxolitinib Cream for Treatment of Atopic Dermatitis U.S. Pharmacist [ cited 2021 Dec 23]. Available from: https://www.uspharmacist.com/article/fda-approves-ruxolitinib-cream-for-treatment-of-atopic-dermatitis
   Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863–872.
   PubMed Web of Science ®Google Scholar
• Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021;5(1):293–304.
   PubMedGoogle Scholar
• Leo. Expanded Access Policy [ cited 2022 Feb 27]. Available from: https://www.leo-pharma.us/Home/Our-Pipeline/Expanded-Access-Policy.aspx
   Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020 Apr;82(4):823–831.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021 Oct 1;85(4):854–862.
   PubMed Web of Science ®Google Scholar
• Gavidia M FDA approves abrocitinib for adults with moderate to severe atopic dermatitis: AJMC; [ cited 2022 Feb 27]. Available from: https://www.ajmc.com/view/fda-approves-abrocitinib-for-adults-with-moderate-to-severe-atopic-dermatitis
   Google Scholar
• Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014 Aug 15;462(1):1–13.
   PubMedGoogle Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020Jul25; 396(10246)255–266. (London, England)
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Thyssen JP, Simpson EL, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol. 2021 Jul;22(4):541–554.
   PubMed Web of Science ®Google Scholar
• Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol JEADV. 2022;36(3):422–433.
   Web of Science ®Google Scholar
• Newswire CP Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis 2022 [Feb 27 2022]. Available from: https://www.prnewswire.com/news-releases/updates-on-olumiant-baricitinib-phase-3-lupus-program-and-fda-review-for-atopic-dermatitis-301470359.html
   Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020 Aug;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021 Jul;85(1):62–70.
   PubMed Web of Science ®Google Scholar
• Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427–443.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial [10.1111/jdv.17278]. J Eur Acad Dermatol Venereol. 2021 Jul 1;35(7):1543–1552.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691–699.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, de Bruin-weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e14.
   Web of Science ®Google Scholar
• Blauvelt A. Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial. D1T01. 3B, EADV Congress; 2021.
   Google Scholar
• Silverberg JI, Hong C, Thyssen JP, et al. Comparison of efficacy of targeted therapies without topical corticosteroids for moderate to severe atopic dermatitis: systematic review and network meta-analysis. Revolutionizing Atopic Dermitis Meeting June 2021
   Google Scholar
• Silverberg JI, Thyssen JP, Fahrbach K, et al., Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol JEADV. 35(9): 1797–1810. 2021.
   PubMed Web of Science ®Google Scholar
• Cohen BL. Janus kinase signaling in inflammatory bowel disease. Gastroenterol Hepatol. 2021;17:278–281.
   Google Scholar
• Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022 Jan;86(1):104–112.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395.
   PubMed Web of Science ®Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.
   PubMed Web of Science ®Google Scholar
• F R, L R, S JS. Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum. 2016 Dec 1;46(3):279–285.
   PubMed Web of Science ®Google Scholar
• PFIZER shares co-primary endpoint results from post-marketing required safety study of XELJANZ® (TOFACITINIB) in subjects with rheumatoid arthritis (RA) [Internet]. 2021 Jan 27 [cited May 8, 2021]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing
   Google Scholar
• Murphrey M, Waldman RA, Durso T, et al. Special editorial: when prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the food and drug administration’s september 1, 2021, data safety communication. J Am Acad Dermatol. 2022 Jan;86(1):42–43.
   PubMed Web of Science ®Google Scholar
• Tsai H-R, J-w L, Chen L-Y, et al. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021;11(4):279.
   PubMed Web of Science ®Google Scholar
• Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020 Dec 1;40(12):2117–2118.
   PubMed Web of Science ®Google Scholar
• López-Fauqued M, Co-van der Mee M, Bastidas A, et al. Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials. Drug Saf. 2021;44(7):811–823.
   PubMed Web of Science ®Google Scholar
• Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Vol. 58. England: Rheumatology (Oxford; 2019. p. i43–i54.
   Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION. RINVOQ® (upadacitinib) extended-release tablets, for oral use initial U.S. In: Approval: 2019 In: FDA US. editor: U.S. FDA; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211675s008lbl.pdf
   Google Scholar
• FDA US. HIGHLIGHTS OF PRESCRIBING INFORMATION; OLUMIANT (baricitinib) tablets, for oral use, editor. FDA US; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf
   Google Scholar
• FDA US. HIGHLIGHTS OF PRESCRIBING INFORMATION; OPZELURA™ (ruxolitinib) cream, for topical use. FDA US: editor. Available from: https://www.opzelura.com/prescribing-information.pdf
   Google Scholar
• Gooderham M, Girolomoni G, Moore JO, et al. Durability of Response to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial AAD VMX 2021 Virtual Meeting Experience 2021
   Google Scholar
• Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine [Internet]. [cited 17 July 2021]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-top-line-results-phase-3-study-breeze
   Google Scholar